Press release: CapMan Life Science IV holds first closing at EUR 45
million
(24 March 2006) - CapMan Plc has established its fourth life science
fund. The first closing of CapMan Life Science IV was held today at EUR 45
million. CapMan Life Science IV will invest in medical technology
companies mainly in the Nordic countries. The establishment of the fund
does not have a substantial impact on CapMan’s result for 2006.
The target for the fund is EUR 100 million. CapMan’s own commitment
into the fund is EUR 5 million. The management fee of CapMan Life Science
IV fund is in accordance with common practice in the industry. In
connection with the establishment of the fund, the Board of Directors of
CapMan Plc decided that 50% of CapMan Life Science IV’s possible carried
interest will be distributed to the members of the investment team
responsible for the fund’s investment activities during its life cycle.
A new fund typically starts to generate carried interest after 5 to 7
years, provided that the investors have regained their investment and an
8% preferred annual return.
For further information please contact:
Jan Lundahl, Senior Partner, Head of CapMan Life Science, tel. +46 8
545 854 75 or +46 708 56 19 53
Jerome Bouix, Partner, Fundraising, IR and Communications, tel. +358 9
6155 8358 or +358 40 820 8541
|
